Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Acquisition of Fusion completed | 5 Jun 2024 |
| Tagrisso plus chemo recommended for approval in EU | 3 Jun 2024 |
| Total Voting Rights | 3 Jun 2024 |
| Block listing Interim Review | 3 Jun 2024 |
| Dato-DXd improved OS in nonsquamous lung cancer | 28 May 2024 |
| AstraZeneca to deliver $80bn revenue by 2030 | 21 May 2024 |
| AstraZeneca to manufacture ADCs in Singapore | 20 May 2024 |
| SUPERNOVA Trial Met COVID-19 prevention endpoint | 16 May 2024 |
| Director/PDMR Shareholding | 15 May 2024 |
| AstraZeneca completes Cellectis equity investment | 7 May 2024 |
| Calquence combination improved PFS in 1L MCL | 2 May 2024 |
| Total Voting Rights | 1 May 2024 |